Detalhe da pesquisa
1.
Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study.
Pediatr Allergy Immunol
; 35(5): e14131, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700124
2.
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
Hum Vaccin Immunother
; 20(1): 2348135, 2024 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38738683
3.
Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
Lancet Infect Dis
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38701823
4.
[Hepatitis A outbreak in Galicia during 2016-2018]. / Brote de hepatitis A en Galicia durante 2016-2018.
Rev Esp Salud Publica
; 942020 Jan 24.
Artigo
em Espanhol
| MEDLINE | ID: mdl-31974339